Fig. 6.
Dual inhibition of PI3K and mTOR reduces tumor growth in a preclinical RMS mouse model. a Schema depicting preclinical study design to determine whether GSK2126458 is effective in inhibiting M25.FGFR4V550E tumor growth. b Disease-specific survival (DSS) illustrates statistically significant increased survival in mice treated with GSK2126458 when compared to vehicle-treated (control) (p < 0.001) or vincristine-treated cohorts (p = 0.03). Murine cohorts treated with the combination of vincristine and GSK2126458 also significantly increased DSS (p = 0.04). c Normalized hind limb volume calculations demonstrate variability among individual mice in the four cohorts. Treatment with GSK2126458 significantly reduced tumor size compared to vehicle-treated controls (p < 0.05). Statistical significance was analyzed with two-tailed t-test. Points represent mean ± SEM